Navigation Links
MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
Date:11/28/2007

- First Patient Implanted in San Antonio, TX -

ORANGEBURG, N.Y., Nov. 28 /PRNewswire/ -- MetaCure Limited, today announced that it began patient enrollment in a national diabetes clinical trial of its TANTALUS(R) System, an investigational device being tested in patients with type 2 diabetes who are overweight. The study is being conducted in up to 30 sites in the United States.

The 300-patient trial will evaluate the TANTALUS, an implantable device that delivers electrical pulses to the stomach when a person eats. The primary objective of the randomized, double-blind controlled study is to evaluate the TANTALUS System in treating patients who have type 2 diabetes and are overweight. Impact on blood glucose levels, weight loss, blood pressure and other clinical and metabolic parameters will be studied. To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type 2 diabetes with a body mass index (BMI) between 28 and 45 kg/m2 and ages 18 to 70.

"Even with current medications and lifestyle changes, controlling blood glucose levels in type 2 diabetes patients who are overweight can be difficult," said Naji N. Abumrad, MD, MetaCure's Medical Director and John L. Sawyers Professor of Surgery and Chairman, Department of Surgery at Vanderbilt University Medical Center, Nashville, TN. "We are excited to have this trial underway as a potential alternative treatment for patients where we have been unsuccessful in managing their type 2 diabetes and weight."

Glandular Diseases Center of San Antonio, Texas, is the first trial site to enroll patients. "We are delighted to be participating in this trial and to be the initial center to implant the TANTALUS System in study patients," said Mark Kipnes, MD, of the Glandular Diseases Center.

"The TANTALUS System is currently CE marked and available to patients in Europe for the indication to treat type 2 diabetes with obesity. It has been clinically evaluated in more than 100 patients world wide," explained Dr. Irit Yaniv, MetaCure's Chief Operating Officer. "We look forward to potentially being able to make it accessible in the future to U.S. patients as well."

For more information about the study, please go to http://www.metacure.com.

More About the TANTALUS System

The TANTALUS System includes a pulse generator and leads that are implanted through a minimally invasive laparoscopic procedure that can be performed in an outpatient setting. The leads are implanted in the gastric muscle and the device is implanted in a subcutaneous pocket.

The system is based on new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meal times.

About MetaCure

MetaCure Limited was founded in 2003 and is developing minimally invasive solutions for today's most pressing global epidemic, type 2 diabetes. Its flagship product, the TANTALUS System, has already been granted the CE mark in Europe. The company's corporate U.S. offices are based in Orangeburg, New York, and Mt. Laurel, New Jersey. For more information, visit http://www.metacure.com.

Media Contact For MetaCure:

Erich Sandoval of Lazar Partners

Tel. 212-867-1773

E-mail: esandoval@lazarpartners.com


'/>"/>
SOURCE MetaCure Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
6. Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: